Eli Lilly
Indianapolis-based pharmaceutical company founded in 1876. It reported 2025 revenue of USD 65.2 billion and has been represented in Saudi Arabia since 1983.
Industry: Pharmaceuticals | Location: Indianapolis, United States | Founded: 1876
About Eli Lilly
Eli Lilly and Company, known as Lilly, is a pharmaceutical company headquartered in Indianapolis, Indiana. Its 2025 Form 10-K groups its medicines and pipeline into cardiometabolic health, which includes diabetes and obesity, immunology, neuroscience and oncology. At the end of 2025 it had about 50,000 employees, including about 12,000 in research and development. It lists production sites in the United States, Ireland, France, Spain, Italy, China and Japan.
Wikipedia states that Lilly was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union Army veteran. David Ricks has been chair, president and chief executive since 2017. The filing's executive officers include Lucas Montarce as chief financial officer, Daniel Skovronsky as chief scientific and product officer and Patrik Jonsson as president of Lilly International.
Mounjaro and Zepbound together made up 56 percent of 2025 revenue, with Mounjaro at USD 22,965 million and Zepbound at USD 13,542 million. Verzenio, Trulicity, Taltz and Jardiance each also exceeded USD 3 billion in revenue, and the six products made up 82 percent of the total.
In the Middle East, Lilly says it has been represented in Saudi Arabia since 1983, set up a fully owned Saudi legal entity in 2018 and was the first pharmaceutical company to join the Regional Headquarters initiative, with operations placed in Riyadh. In March 2021 it signed a memorandum with the Saudi Ministry of Investment on a regional headquarters in the King Abdullah Financial District, and in August 2021 a memorandum with AJA Pharma, a Saudi Chemical Holding unit, to make its insulin products locally. TechScoop reported in May 2026 that Isomorphic Labs holds research partnerships with Lilly, Novartis and Johnson & Johnson.
Lilly recorded USD 3.0 billion of acquired in-process research and development in 2025, mainly for Scorpion Therapeutics' STX-478 programme and SiteOne Therapeutics. Its filing also refers to acquisition agreements signed in early 2026.
Lilly reported 2025 revenue of USD 65,179 million, against USD 45,043 million in 2024, and net income of USD 20,640 million, against USD 10,590 million. It paid dividends of USD 6.00 per share in 2025.
Leadership
- David Ricks, Chair, President and Chief Executive Officer
- Lucas Montarce, Executive Vice President and Chief Financial Officer
- Anat Hakim, Executive Vice President, General Counsel and Secretary
- Daniel Skovronsky, Executive Vice President, Chief Scientific and Product Officer, and President, Lilly Research Laboratories
- Patrik Jonsson, Executive Vice President and President, Lilly International
- Ilya Yuffa, Executive Vice President and President, Lilly USA and Global Customer Capabilities
- Jacob Van Naarden, Executive Vice President, President, Lilly Oncology, and Head of Corporate Business Development
- Diogo Rau, Executive Vice President and Chief Information and Digital Officer